Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs

https://doi.org/10.1016/S1590-8658(00)80840-3Get rights and content

Abstract

Background & Aim. New class of nitric oxide-releasing non-steroidal anti-inflammatory drugs was shown to inhibit cyclooxygenase and prostaglandin generation without causing mucosal damage but whether these agents are capable of affecting gastric mucosal damage induced by strong irritants and healing of chronic gastric ulcers remains to be studied. In this investigation, effects of nitric oxide-releasing aspirin and nitric oxide-releasing naproxen were compared with those of native agents on gastric lesions provoked by 100% ethanol and on healing of chronic acetic acid ulcers.

Results. Both, nitric oxide-releasing aspirin and naproxen dose-dependently attenuated ethanol-induced damage and produced a significant rise in gastric blood flow but did not delay healing of gastric ulcers while native aspirin and naproxen had no influence on ethanol-induced gastric damage but significantly prolonged ulcer healing, reduced gastric blood flow and suppressed mucosal generation of prostaglandin E2. The gastroprotective and hyperaemic effects of both nitric oxide-non-steroidal anti-inflammatory drugs were completely abolished by ODD, an inhibitor of guanylyl cyclase-CGMP system but not influenced by suppression of nitric oxide-synthase with L-NNA. The damaging effects of native acetyl salicylate acid or naproxen were aggravated by acidification of these non-steroidal anti-inflammatory drugs but the exogenous acid added to nitric oxide-acetyl salicylate acid or nitric oxide-naproxen failed to influence their effect. Despite inhibiting of PGE2 generation, both nitric oxide-releasing derivatives and native aspirin and naproxen failed to affect expression of cyclooxygenase-1 mRNA but upregulated the cyclooxygenase-2 mRNA. Concurrent inhibition of cyclooxygenase-2 by selective inhibitor NS-39B which by itself delayed ulcer healing and attenuated the gastric blood flow at ulcer margin, significantly worsened the effects of these nitric oxidenon-steroidal anti-inflammatory drugs and their parent drugs on ulcer healing and the gastric blood flow at the ulcer margin.

Conclusions. 1) Coupling of nitric oxide to aspirin or naproxen attenuates ethanol-induced damage, possibly due to an increase in gastric microcirculation mediated by excessive release and action of nitric oxide that probably compensates for PG deficiency induced by non-steroidal anti-inflammatory drugs; and 2) nitric oxide-non-steroidal anti-inflammatory drug, unlike classic non-steroidal anti-inflammatory drugs, does not affect intact gastric mucosa and fails to delay the healing of pre-existing ulcers.

References (38)

  • T. Brzozowski et al.

    Role of prostaglandin-generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion induced gastric lesions

    Eur J Pharmacol

    (1999)
  • B.P. Kennedy et al.

    Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA

    Biochem Biophys Res Commun

    (1993)
  • S. Fiorucci et al.

    Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats

    Gastroenterology

    (1999)
  • B.S. Anand et al.

    Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects

    Am J Gastroenterol

    (1999)
  • H. Mizuno et al.

    Induction of cyclooxygenase-2 in gastric mucosa lesions and its inhibition by the specific antagonist delays healing in mice

    Gastroenterology

    (1997)
  • N.M. Davies et al.

    NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects

    Aliment Pharmacol Ther

    (1997)
  • J.L. Wallace et al.

    Anti-thrombotic effects of a nitric oxide-releasing, gastric sparing aspirin derivative

    J Clin Invest

    (1995)
  • K. Takeuchi et al.

    Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses

    J Physiol Pharmacol

    (1998)
  • S. Moncada et al.

    Nitric oxide: Physiology, pathophysiology and pharmacology

    Pharmacol Rev

    (1991)
  • Cited by (47)

    • Therapeutic role of nitric oxide as emerging molecule

      2017, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      The suppression of ROS (reactive oxygen species) is responsible for gastroprotection against gastric acute lesions induced by 3.5 h of WRS (water immersion restraint). These analogues cause an attenuation of lipid peroxidation, decrease of MDA and 4-HNE levels and enhancement of antioxidative properties as evidenced by increase of SOD activity [186]. Novel dihydroartemisinin-nitric oxide donor hybrid based derivatives such as compound 49 have been designed and synthesized as multitarget agents.

    • The nitric oxide donor cis-[Ru(bpy)<inf>2</inf>(SO<inf>3</inf>)NO](PF<inf>6</inf>) increases gastric mucosa protection in mice - Involvement of the soluble guanylate cyclase/K<inf>ATP</inf> pathway

      2015, Nitric Oxide - Biology and Chemistry
      Citation Excerpt :

      We demonstrated that inhibition of soluble guanylate cyclase completely abolished the protective effect of FOR0810 in two models of gastric damage. Our results are compatible with those obtained by Brzozowski et al. [34], who found that ODQ treatment completely abolished the protective effect of NO-releasing NSAIDs against ethanol-induced gastric damage. The participation of KATP channels in several models of gastric protection was previously described [4,9,35].

    View all citing articles on Scopus
    View full text